Markers for diagnosing infections

The measurement of specific protein combinations in a blood sample addresses the challenge of diagnosing infectious disease prognosis, enabling timely and accurate patient management strategies.

WO2026069328A1 Publication Date: 2026-04-02MEMED DIAGNOSTICS LTD
2 Cites 0 Cited by

Patent Information

Application Number
PCT/IL2025/050856
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-04-22
Filing Date
2025-09-26
Publication Date
2026-04-02

AI Technical Summary

Technical Problem

Current methods for diagnosing infectious diseases lack efficient and timely identification of patient prognosis, leading to inadequate or excessive management strategies, which can impact patient outcomes.

Method used

A method involving the measurement of specific protein combinations in a blood sample, including Angiopoietin-2, Interleukin 1 receptor-like 1, Interferon gamma-induced protein 10, Interleukin-6, Tumor necrosis factor ligand superfamily member 10, and Tumor necrosis factor receptor superfamily member 10B, to diagnose and predict the severity of infectious diseases.

Benefits of technology

Enables timely and accurate diagnosis of infectious disease severity, allowing for appropriate patient management strategies, including aggressive or less aggressive interventions based on the disease's prognosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A method of determining the severity of the disease, in a subject comprising measuring an expression level of at least one protein selected from the group consisting of IP- 10, IL-6, IL- 10, DR5, ANG-2 and ST2 in a sample of the subject; and determining the severity of the disease based on said expression level. Kits for carrying out diagnosis are also disclosed.
Need to check novelty before this filing date? Find Prior Art